Fig. 3: Kaplan-Meier plots for overall survival comparing ELN 2022 risk groups to the individual myelodysplasia-related gene mutations. | Leukemia

Fig. 3: Kaplan-Meier plots for overall survival comparing ELN 2022 risk groups to the individual myelodysplasia-related gene mutations.

From: Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

Fig. 3

Patients from the entire cohort were retrospectively assigned to ELN 2022 risk groups. Patients within the ELN 2022 adverse risk group that had MR gene mutation were treated as a separate group for this Kaplan-Meier analysis. The individual gene mutations are (A) ASXL1, (B) BCOR, (C) EZH2, (D) SF3B1, (E) SRSF2, (F) STAG2, (G) U2AF1 and (H) ZRSR2. Log rank p values are reported for the distinction between patients with MR gene mutation and patients with ELN 2022 adverse risk (MR gene mutation excluded).

Back to article page